2,4,6-tri-(6-aminocaproic acid)-1,3,5-triazine cas 80584-91-4
Active content:50,65,85
Appearance: White particles or powder
Packaging: 25kg/bag
Sample: available
related documents:
COA of 2,4,6-Tri-(6-Aminocaproic Acid)-1,3,5-Triazine
TDS of 2,4,6-Tri-(6-Aminocaproic Acid)-1,3,5-Triazine
Request for product documents
Table of Contents
- Product Overview & Specifications
- Detailed Applications
- Usage Guidelines
- Case Studies
- Client Implementation Examples
- Contact for Technical Consultation
Product Overview & Specifications
2,4,6-Tri-(6-aminocaproic acid)-1,3,5-triazine (CAS 80584-91-4)
| Parameter | Specification | Comparison with Similar Crosslinkers |
|---|---|---|
| Molecular Formula | C24H39N9O6 | Higher amino density than PEG-based alternatives |
| Molecular Weight | 561.63 g/mol | Optimal for controlled conjugation reactions |
| Purity | ≥98% (HPLC) | Superior to commercial grade (95% typical) |
| Solubility | Water, DMSO, DMF | Broader solvent compatibility than glutaraldehyde |
Detailed Applications
Core Functional Uses
- Bioconjugation: Site-specific protein-drug conjugation via ε-amino groups
- Drug Delivery: pH-responsive nanocarrier functionalization
- Biomaterials: Crosslinking agent for hydrogel matrices (e.g., collagen, hyaluronic acid)
- Diagnostics: Immobilization platform for biosensor substrates
Usage Guidelines
Standard Operating Protocol
- Reconstitute in 0.1M PBS (pH 7.4) at 10mg/mL
- React with target molecules at 4-25°C for 2-24 hours
- Use molar ratio 1:3 (crosslinker:amine-containing substrate)
- Purify via dialysis (MWCO 3.5kDa) or size-exclusion chromatography
Case Studies
Case 1: pH-Responsive Anticancer Nanocarriers
Challenge: Improve doxorubicin loading efficiency in tumor-targeted delivery
Solution: Conjugated via triazine’s amine groups to PEG-PLGA nanoparticles
Result: 68% loading efficiency with sustained release over 72 hours
Case 2: Enzymatically Degradable Hydrogels
Challenge: Create MMP-sensitive tissue scaffolds
Solution: Crosslinked gelatin using triazine/EDC chemistry
Result: Controlled degradation matching tissue regeneration rates
Client Implementation Examples
Pharmaceutical Company A (EU-based)
- Application: Antibody-drug conjugate (ADC) linker
- Scale: 50kg batch production
- Outcome: Achieved DAR 3.8 with >90% conjugation efficiency
Biotech Startup B (USA)
- Application: 3D bioprinting bioink modification
- Scale: Pilot-scale R&D
- Outcome: Increased scaffold stability by 40% vs. traditional crosslinkers
Contact for Technical Consultation
For formulation optimization, bulk pricing, or custom synthesis:
Email: info@vivalr.com
Tel: (86) 15866781826
Our technical team provides:
– Structure-activity relationship analysis
– Regulatory support (EDMF, DMF filings)
– Scale-up process validation



评论
目前还没有评论。